Flavia Hoyte, MD
Professor of Medicine, Division of Allergy and Immunology
Director, Allergy and Clinical Immunology Fellowship Program
National Jewish Health/University of Colorado
Denver, Colorado
Stella Lee, MD
Section Chief - Rhinology
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
Michael E. Wechsler, MD, MMSc
Professor, Department of Medicine
Director, The Cohen Family Asthma Institute
Division of Pulmonary, Critical Care and Sleep Medicine
Director, Asthma Program
National Jewish Health
Denver, Colorado

Target Audience

The educational design of this activity addresses the needs of clinical immunology and pulmonology clinicians who manage patients with chronic inflammatory airway diseases.

Program Overview

Chronic inflammatory diseases of the upper and lower airways, including allergic rhinitis, chronic rhinosinusitis with nasal polyps (CRSwNP), and asthma, have been tied to significant risks and burdens for affected patients. Although biologic therapies that target overactive cytokine signaling are available, newer therapies are emerging, with targets upstream in the pathogenic cascade to improve efficacy across both T2-high and T2-low profiles. Join us for this engaging Expert Roundtable to hear multidisciplinary insights related to pathophysiologic processes in chronic inflammatory airway diseases, the rationale and evidence behind new biologic therapies, and integrated therapeutic strategies to achieve global disease control.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe the overlapping pathophysiologic processes that contribute to chronic inflammation, hyperresponsiveness, and remodeling in the upper and lower airways, including their implications for treatment
  • Discuss the clinical profiles of and evidence for biologic therapies to address overactive cytokine signaling in patients with chronic inflammatory upper or lower airway diseases
  • Tailor biologic-based therapeutic regimens for patients with severe asthma, allergic rhinitis, and/or CRSwNP to account for underlying disease processes and overcome treatment-related barriers

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Flavia Hoyte, MD: Consulting Fees: AstraZeneca plc, Genentech, Sanofi-Aventis U.S. LLC, Teva Pharmaceutical Industries Ltd., GSK; Contracted Research: Institution received research support from Genentech, Inc., Sanofi-Aventis U.S. LLC, GSK plc; Fees for Non-CE Services Received Directly From an Ineligible Entity or Their Agents: AstraZeneca plc, Genentech; Stock Shareholder: Amgen

Stella Lee, MD: Consulting Fees: AstraZeneca plc, Genentech, GSK plc, Lyra Therapeutics, OptiNose, Sanofi Regeneron; Contracted Research: AstraZeneca plc, Genentech, GSK plc, Lyra Therapeutics, OptiNose, Sanofi Regeneron

Michael E. Wechsler, MD, MMSc: Consulting Fees: Amgen, Inc., Areteia Therapeutics, Inc., AstraZeneca plc, Avalo Therapeutics, Inc., Boehringer Ingelheim, Celldex Therapeutics, Inc., Cerecor Inc, Cohero Health, CytoReason, Eli Lilly and Company, Equillium, GSK plc, Incyte, Kinaset Therapeutics, Merck & Co., Novartis Pharmaceuticals Corporation, OM Pharma SA, Foresite Labs, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc., resTORbio, Genentech, Inc., Sanofi S.A., Sentien Biotechnologies, Inc., Sound Biologics, Tetherex Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Upstream Bio

The planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a minimum score of 75% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For questions about this activity, please contact us at info@exchangecme.com.

Begin Activity
available resources
meeting slides
interactive presentation
linked resources
Suggested Reading
Expert Roundtable™

Chronic Inflammatory Airway Diseases

Expert Insights on Unifying Management Paradigms